|Day Low/High||14.60 / 15.00|
|52 Wk Low/High||7.86 / 16.95|
Data show M230's ability to block immune complex-mediated damage and robust efficacy in preclinical
-- Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio --
Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio
Momenta Pharmaceuticals' (MNTA) stock rating was raised to 'overweight' at Barclays on Tuesday.
Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.
Shire to continue to fund the M923 program for twelve months and will transfer all remaining clinical, regulatory and commercialization activities to Momenta
Investors in Momenta Pharmaceuticals Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new November 18th contracts and identified one put and one call contract of particular interest.
The market action is solid today as my hunt for individual stock picks continues.
In trading on Friday, shares of Momenta Pharmaceuticals Inc crossed above their 200 day moving average of $12.28, changing hands as high as $12.83 per share. Momenta Pharmaceuticals Inc shares are currently trading up about 14.4% on the day.
After a Supreme Court setback to the federal crackdown on insider trading, U.S. Attorney Preet Bharara signals his intent to forge ahead with new indictments reminiscent of the SAC case.
Novel oncology candidate necuparanib had favorable tolerability and encouraging signals of activity in Phase 1 study
Stocks with insider trader activity include STS, RRGB and MNTA